|
Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database. |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Amgen; Merck Serono; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER |
Speakers' Bureau - Merck Serono |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER |
|
|
Stock and Other Ownership Interests - Acceleron Pharma; Aimmune; Alnylam; Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Global Blood Therapeutics; GW Pharmaceuticals; Madrigal Pharmaceuticals; Moderna Therapeutics; Myovant Sciences; Opthea; Orphazyme; Sangamo Bioscience; Twist Bioscience; UniQure; Vertex; Zogenix |
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax |
Consulting or Advisory Role - Center for Emerging & Neglected Diseases (CEND); Deciphera; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Specialised Therapeutics; Targovax |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Helsinn Healthcare; Incyte; Ipsen; Janssen Research & Development; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Pierre Fabre; Roche; Seagen; SERVIER; Sirtex Medical; Taiho Oncology; TERUMO; Trigemina; Zymeworks |
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies |
Consulting or Advisory Role - AstraZeneca; Bayer; Compass Therapeutics; G1 Therapeutics; GlaxoSmithKline; Taiho Pharmaceutical; UpToDate |
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Berlin-Chemie; Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Roche; Sanofi |
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Lilly/ImClone; Merck Serono; Merck Sharp & Dohme; Novartis; Sanofi |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycotope GmbH (Inst); Incyte (Inst); IO Biotech (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); SpringWorks Therapeutics (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pfizer; Sanofi |
|
|
Employment - Genentech/Roche |
Other Relationship - Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical |
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck |
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva |
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst) |